Asoprisnil (J867) is an investigational selective progesterone receptor modulator developed by Schering and TAP Pharmaceutical Products tested for treatment of progesterone sensitive myomata.In 2005 Phase III trials were discontinued due to endometrial changes in patients. It is uncertain whether asoprisnil will be marketed.
This page contains content from the copyrighted Wikipedia article "Asoprisnil"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
